Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

October 1, 2012
PresentationTivozanib

ESMO 2012: Detailed comparison of the safety of tivozanib hydrochloride versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a Phase III trial

October 1, 2012
PresentationTivozanib

ESMO 2012: Patient preference for tivozanib hydrochloride or sunitinib in the treatment of metastatic renal cell carcinoma (mRCC): TAURUS study design

October 1, 2012
PresentationTivozanib

ESMO 2012: Tivozanib hydrochloride pharmacokinetic/pharmacodynamic analysis of blood pressure and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma

September 30, 2012
PresentationFiclatuzumab

ESMO 2012: Pharmacodynamic–pharmacokinetic study of ficlatuzumab, a monoclonal antibody directed to the hepatocyte growth factor (HGF), in patients with advanced solid tumors who have liver metastases

September 29, 2012
PresentationFiclatuzumab

ESMO 2012: A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab, a humanized hepatocyte growth factor (HGF) inhibitory monoclonal antibody, in combination with gefitinib versus gefitinib alone in Asian patients with lung adenocarcinoma

June 2, 2012
PresentationTivozanib

ASCO 2012: A Phase II Biomarker Assessment of Tivozanib in ONcology trial in patients (pts) with advanced renal cell carcinoma (BATON RCC)

1 … 9 10 11 12 13 … 15

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.